<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="442">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581503</url>
  </required_header>
  <id_info>
    <org_study_id>NIH/LAMMP-2006-4981</org_study_id>
    <nct_id>NCT00581503</nct_id>
  </id_info>
  <brief_title>Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer</brief_title>
  <official_title>Optical Coherence Tomography for Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beckman Laser Institute University of California Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to utilize already obtained biopsy specimens for investigation
      of the utility of a new, non-invasive optical diagnostic technique. The study will allow a
      careful correlation between the Optical coherence tomography findings and conventional
      histology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optical coherence tomography is a non-invasive diagnostic technique that can provide
      information about tissue abnormalities, change in structure of an organ. This technique uses
      a near-infrared diode to emit light that can produce images of the specimen under
      investigation without causing damage or alterations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Pathology results.</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Pleural Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>diagnostic</arm_group_label>
    <description>oct imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>diagnostic</intervention_name>
    <description>oct imaging</description>
    <arm_group_label>diagnostic</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study Population will be identified at UCIMC, who is scheduled for prostatectomy,
        endobronchial, transbronchial, and pleural biopsy will be recurited to participate in the
        study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult 18 years and older

          -  Having procedure of endobronchial, transbronchial, and / or pleural biopsy

        Exclusion Criteria:

          -  Currently participating in any other investigational drug or device evaluation.

          -  Currently taking drugs that are sensitive to light.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Brenner, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beckman Laser Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Brenner, M.D</last_name>
    <phone>(714)456-5150</phone>
    <email>mbrenner@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sari Mahon, PhD</last_name>
    <phone>(949)824-3924</phone>
    <email>mahonsb@uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pulmonary and Critical Care Medicine, UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Brenner, M.D</last_name>
      <phone>714-456-5150</phone>
      <email>mbrenner@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sari Mahon, PhD</last_name>
      <phone>(949) 824-3924</phone>
      <email>mahonsb@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Brenner, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Ahlering, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Skarecky, M</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Mukai, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology department, UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Brenner, M.D</last_name>
    </contact>
    <contact_backup>
      <last_name>Sari B Mahon</last_name>
      <phone>(949) 824-3924</phone>
      <email>mahonsb@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Brenner, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Ahlering, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 5, 2016</lastchanged_date>
  <firstreceived_date>December 19, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Beckman Laser Institute and Medical Center</investigator_full_name>
    <investigator_title>Matthew Brenner, M.D.,Department of Pulmonary and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>early detection of lung and pleural cancer</keyword>
  <keyword>early detection of prostate cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
